DPP4 and type 2 diabetes mellitus: In our current MMT study, T2DM subjects with DPP-4 inhibitor treatment presented significantly elevated postprandial active GIPbioassay than those of T2DM without the treatment, similarly to our previous study examined in NGT subjects (9).